US · Healthcare · Biotechnology
EPS came in at -1.05 against a street estimate of -0.98 — a miss of 7.1%.
Analysts rate ArriVent BioPharma, Inc. Common Stock a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $22.78.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 9.16% |
| Hillhouse Capital Advisors, Ltd. | 7.97% |
| BlackRock Inc | 6.59% |
| Orbimed Advisors LLC | 6.14% |
| FMR Inc | 5.64% |
| Octagon Capital Advisors LP | 4.00% |
| Vanguard Capital Management, LLC | 3.60% |
| Sofinnova Ventures | 3.44% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • ArriVent BioPharma announced that it dosed the first patient in a U.S. Phase 1 clinical trial of ARR-002 on October 12, 2026. • A | 2026-10-13 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • ArriVent BioPharma issued a Form 8-K on October 6, 2026, regarding an update from the Phase 3 FURVENT trial. • The trial is evalu | 2026-10-06 |
| Quarterly report · Q2 2026 ARRIVENT BIOPHARMA, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $154.7 million in cash and cash equivalents as of June 30, 2026, u | 2026-08-12 |
| Results announced · Q3 2026 ARRIVENT BIOPHARMA Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash and investments: $373.1 million as of June 30, 2026 • Expected to fund operatio | 2026-08-12 |
| Shareholder vote results · Q2 2026 ARRIVENT BIOPHARMA, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company held 2026 annual stockholder meeting on June 18, 2026 • 46,368,442 shares of commo | 2026-06-22 |
| Quarterly report · Q1 2026 ARRIVENT BIOPHARMA, INC. — Q1 2026 SUMMARY HEADLINE NUMBERS • Cash and investments: $326.4 million (cash $62.1M + short-term investments $264.3M) as | 2026-05-11 |
| Company announcement · Q2 2026 ARRIVENT BIOPHARMA, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company authorized to offer up to $250,000,000 in common stock through an "at the mar | 2026-05-11 |
| Results announced · Q2 2026 ARRIVENT BIOPHARMA Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash and investments: $326.4 million as of March 31, 2026 • Cash runway: expected to | 2026-05-11 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ArriVent BioPharma, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.